By the Weight Loss Provider Guide Editorial Team · Last verified: May 15, 2026 · Next scheduled review: August 15, 2026 (or sooner if any drug's label revises) · Educational information, not medical advice. Confirm any decision with your own prescriber.
GLP‑1 and Gallstone History: Can You Take a GLP‑1 If You've Had Gallstones?
Last updated: · Last verified: May 15, 2026
A history of gallstones is not an automatic "no" for the GLP‑1 and dual-incretin medications covered on this page — but it is also not nothing. GLP‑1 and gallstone history is one of the most common reasons people pause before starting Wegovy, Zepbound, Mounjaro, Ozempic, Saxenda, or the new oral Foundayo (orforglipron). Here's the bottom line: prior gallstones, prior gallbladder removal, and a family history of gallstones are not listed as label contraindications for any of the products reviewed here.
We read every current U.S. label for these drugs ourselves. We pulled the numbers below directly from the FDA-approved prescribing information at accessdata.fda.gov. Below you'll find a 30-second decision matrix, a cross-drug incidence table, a symptom triage box for if you're already on a GLP‑1 and something feels off, and a script you can take into your next appointment so nothing gets missed.
If your history is silent stones from a decade ago and your gallbladder is still in place: you may still be a candidate, with disclosure and a symptom plan.
If your history is a gallstone attack last month or pancreatitis last year: pause and talk to your prescriber before you click "start."
If you're 8 weeks into Zepbound and there's a sharp pain under your right rib: scroll to the triage box first.
What we actually verified
We read the most current FDA Prescribing Information for Wegovy, Wegovy HD (7.2 mg), Wegovy oral tablets, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, and Foundayo (orforglipron) at accessdata.fda.gov. We pulled label-reported cholelithiasis and cholecystitis percentages directly from those labels. We read the He et al. 2022 JAMA Internal Medicine meta-analysis of 76 trials and 103,371 patients in full. We read the Lilly medical-information statement on tirzepatide and gallbladder history. We verified every number on this page against a primary source — if a source isn't cited below, the number isn't here. We did not invent any figure on this page.
The 30-second answer: GLP‑1 and gallstone history, by scenario
Answer capsule
Prior gallstone history is not listed as a contraindication for the GLP‑1 and dual-incretin products covered on this page. What changes the right next step is which version of "history" applies to you — silent stones, prior symptomatic attacks, prior cholecystitis, prior gallstone pancreatitis, prior gallbladder removal, family history only, or new pain on a GLP‑1 you've already started.
| Your situation | Listed contraindication? | What it means | Safer next step |
|---|---|---|---|
| Silent gallstones found on imaging years ago, no attacks, no pain now | No | Silent stones often stay silent — but rapid weight loss is a known trigger | Disclose. Ask about slower titration and a symptom plan |
| Prior symptomatic gallstones, gallbladder still in place | No | You've already proven your stones can hurt you. Risk of another episode is real but not automatic | Disclose. Discuss drug choice using the table below, plus monitoring |
| Prior cholecystitis (inflamed/infected gallbladder) | No | More serious than uncomplicated colic. Some prescribers want imaging or GI input first | Disclose. Ask if labs or ultrasound are needed before starting |
| Prior gallstone pancreatitis | No, but higher-attention | Pancreatitis from a stone is one of the more serious gallbladder complications. Needs individualized review | Talk to your prescriber, and ideally a GI specialist, before starting |
| Gallbladder removed (cholecystectomy) | No | You can't form new gallbladder stones — bile-duct stones remain uncommonly possible | Disclose date and reason. Plan for GI side-effect overlap with post-surgery bowel changes |
| Family history only, no personal history | No | By itself, family history usually doesn't change label eligibility | Mention it. Your prescriber should still know your full risk picture |
| New right-upper-abdominal pain while on a GLP‑1 | Not a label question — clinical | Could be benign GI side effects, could be a gallbladder event. Symptoms decide | See the triage box. Don't dose-escalate while symptoms are unexplained |
| Severe pain + fever, jaundice, persistent vomiting, dark urine, or clay-colored stools | Not a label question — emergency | Could indicate obstruction, infection, or pancreatitis | Urgent care or ER. Don't drive yourself if symptoms are severe |
This matrix is editorial synthesis based on FDA label language, NIDDK guidance, and peer-reviewed evidence. It is not a personal clearance to take, continue, or stop any medication. Your prescriber owns the prescribing decision.
What "history of gallstones" actually means
Answer capsule
"History of gallstones" can mean seven very different things, and FDA labels treat them the same — but your prescriber probably won't, and shouldn't. The most important distinctions are: are the stones still there, did they ever cause symptoms, did they cause complications, and is your gallbladder still in your body.
What your prescriber needs to know, by history type
| History type | Key missing detail | Why it changes the decision | What to bring |
|---|---|---|---|
| Silent stones | Date found, last imaging, any new symptoms | Rapid weight loss can turn silent stones loud | Imaging report or year |
| Prior symptomatic, gallbladder intact | Frequency and timing of attacks; last episode | Recurrence likelihood; whether to delay or monitor more closely | Attack history with dates |
| Prior cholecystitis | Severity, hospitalization, antibiotics or surgery considered | More serious than colic; may warrant pre-start workup | Records of episode and treatment |
| Prior gallstone pancreatitis | Severity, complications, time since recovery | Adds pancreatitis-recurrence concern to gallbladder-recurrence concern | Discharge summary and labs |
| Cholecystectomy | Surgery date, reason, post-surgery GI status | Removes classic stone risk; bowel changes can overlap with GLP-1 side effects | Op note and current symptoms |
| Family history only | Whose, what type, what age | Baseline risk factor only; doesn't change label eligibility | Brief family summary |
| New pain on GLP-1 | Location, timing, severity, relation to meals | Tells your prescriber if this is GI side effect, gallbladder, or something else | Symptom log + dose history |
Silent gallstones
Stones found on imaging without symptoms. Sometimes called asymptomatic cholelithiasis. NIDDK says most silent gallstones don't need treatment — but rapid weight loss is one of the few reliable ways to turn silent stones into loud ones. About 80% of people with gallstones never develop symptoms. The other 20% find out the hard way.
Prior symptomatic gallstones, gallbladder intact
You had at least one classic gallbladder attack — sudden pain under the right ribs, often after a fatty meal, often lasting a few hours, sometimes radiating to the back or right shoulder. The stones were never removed. Your gallbladder is still in place. You've shown your gallbladder is willing to act up.
Prior cholecystitis
Cholecystitis means the gallbladder itself got inflamed or infected — usually because a stone got stuck. This is more serious than a simple attack and often involves fever, more severe pain, and antibiotics or hospitalization. The standard treatment for repeated cholecystitis is gallbladder removal.
Prior gallstone pancreatitis
A stone slipped out of the gallbladder, traveled down the bile duct, and irritated or obstructed the pancreas. This is the highest-attention history on this list. It can range from mild and self-resolving to severe and life-threatening. If you've had it, your prescriber needs to know — and ideally a GI specialist weighs in before any rapid-weight-loss therapy starts.
Prior cholecystectomy (gallbladder removed)
The organ is gone. You cannot form classic gallbladder stones anymore. You can still — uncommonly — form stones in the bile duct itself (choledocholithiasis). Some people have ongoing bile-acid diarrhea or post-meal cramping after cholecystectomy; that can stack with normal GLP‑1 GI side effects.
Family history only
Mom had her gallbladder out. Or your sister had pancreatitis. You've never had a symptom or an abnormal ultrasound. This is a baseline risk factor — like age, female sex, obesity, or rapid weight loss — but it does not change any FDA label.
Are gallstones a contraindication for GLP‑1 medications?
Answer capsule
No. For the GLP‑1 and dual-incretin products covered on this page, gallstone history is not listed in Contraindications. For most of these products, the key contraindications include product-specific versions of personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and serious hypersensitivity. Gallbladder disease appears in Warnings and Precautions — not in Contraindications.
It matters that you understand three different categories that often get blurred:
- Contraindication. The label says don't use this drug in this situation. Period. For most of the GLP‑1s covered here, that's MTC, MEN 2, and severe hypersensitivity. Gallstone history is not on those lists.
- Warning / precaution. The label says be careful, monitor, evaluate, and counsel the patient. Acute gallbladder disease is in this bucket on every product reviewed here. Warnings don't automatically rule out use; they require prescriber judgment, counseling, and follow-up.
- Provider policy. A telehealth service or a particular prescriber can decline to start you, or require extra documentation, even when the label doesn't ban it. That's a business and clinical-judgment decision, not a regulatory one. Don't read one provider's "we'd need more information" as proof you're permanently disqualified.
Worth repeating: there is no black-box warning for gallbladder disease
For Wegovy, Zepbound, Mounjaro, Saxenda, Ozempic, Trulicity, and Foundayo, the boxed warning is about thyroid C-cell tumors — based on rodent data — not about gallstones. Gallbladder disease appears in Warnings and Precautions. If a TikTok says "GLP‑1s have a black box warning for gallstones," that TikTok is wrong.
What Lilly says (and doesn't say) about tirzepatide
Lilly's official medical-information statement says: tirzepatide use in people with a history of gallbladder disease or prior gallbladder removal is not listed as a contraindication. They also say Lilly cannot provide individual treatment recommendations, and no subgroup analysis was completed in the SURMOUNT or SURPASS trials for patients with prior gallbladder disease or removal. Those patients were not excluded from the trials — they just weren't analyzed separately. "We don't have specific subgroup data" is different from "we won't approve you."
The cross-drug FDA label table: how much gallbladder risk does each GLP‑1 carry?
Answer capsule
In placebo-controlled trials, the rate of new gallstones (cholelithiasis) on the GLP‑1 products covered here ranges from about 0.4% to 2.5%, depending on the drug, dose, and indication. The highest label-reported cholelithiasis rate is Wegovy tablets at 2.5% versus 1% placebo. Among injectable weight-management drugs: Saxenda 2.2% vs 0.8%, Wegovy injection 1.6% vs 0.7%, Zepbound 1.1% vs 1%, Foundayo 1% vs 0.7%. These are not head-to-head comparisons.
| Drug (active ingredient) | Approved for | Cholelithiasis: drug vs placebo | Cholecystitis: drug vs placebo | FDA label warning |
|---|---|---|---|---|
| Wegovy injection (semaglutide 2.4 mg) | Weight management, adults | 1.6% vs 0.7% | 0.6% vs 0.2% | Acute Gallbladder Disease (Warnings & Precautions) |
| Wegovy HD injection (semaglutide 7.2 mg, approved March 2026) | Weight management, adults, high dose | Gallbladder warning applies; no clean separate 7.2 mg rate published apart from standard adult figures | Same | Acute Gallbladder Disease |
| Wegovy oral tablets (semaglutide) | Weight management, adults | ~2.5% vs ~1% | Reported | Acute Gallbladder Disease |
| Ozempic injection (semaglutide 0.5/1 mg) | Type 2 diabetes | 1.5% (0.5 mg) and 0.4% (1 mg) vs 0% placebo | Reported postmarketing | Acute Gallbladder Disease |
| Rybelsus tablets (semaglutide 7/14 mg) | Type 2 diabetes | ~1% (7 mg); 1.1% vs 0.9% (14 mg, 4-year CV outcomes trial) | 1.1% vs 0.7% (14 mg, Trial 7) | Acute Gallbladder Disease |
| Zepbound injection (tirzepatide) | Weight management; obstructive sleep apnea | 1.1% vs 1% (SURMOUNT 1+2 pool) | 0.7% vs 0.2%; cholecystectomy 0.2% vs 0% | Acute Gallbladder Disease |
| Mounjaro injection (tirzepatide) | Type 2 diabetes | Acute gallbladder disease composite 0.6% vs 0% (adult placebo-controlled pool) | Reported in pool | Acute Gallbladder Disease |
| Saxenda injection (liraglutide 3.0 mg) | Weight management, adults | 2.2% vs 0.8% | Reported | Acute Gallbladder Disease |
| Victoza injection (liraglutide 1.2/1.8 mg) | Type 2 diabetes | Not reported as primary endpoint in the same format | Reported | Acute Gallbladder Disease |
| Trulicity injection (dulaglutide) | Type 2 diabetes | Reported in trials; label notes cholelithiasis risk | Reported | Acute Gallbladder Disease |
| Foundayo tablets (orforglipron) | Weight management, adults (FDA-approved April 2026) | 1% vs 0.7% | 0.4% vs 0.3% | Acute Gallbladder Disease |
How to read this table without scaring yourself
- Placebo isn't zero. Look at Zepbound: 1.1% vs 1% placebo. The placebo group still got gallstones. That's because rapid weight loss alone — even without any drug — raises gallstone risk.
- You can't compare drugs directly using these numbers. Trials enrolled different patient populations, used different doses, ran for different durations, and defined gallbladder events slightly differently.
- The labels caught something more than weight loss alone. The Wegovy and Saxenda labels state directly that acute gallbladder disease was greater in treated patients than placebo even after accounting for the degree of weight loss. That supports a medication-associated signal on top of rapid-weight-loss risk.
"Stated vs. verified" — the most common myths, debunked from the actual labels
| Claim you'll see online | What the label and evidence actually say |
|---|---|
| GLP-1s are contraindicated if you have a history of gallstones. | False for the products covered here. None of the GLP-1 or dual-incretin products on this page list gallstone history in Contraindications. For most of these products, the listed contraindications include MTC, MEN 2, and severe hypersensitivity. |
| There's a black box warning for gallstones on GLP-1s. | False. The boxed warning on every product reviewed here is for thyroid C-cell tumors (based on rodent data). Gallbladder disease appears in Warnings and Precautions, not the boxed warning. |
| Tirzepatide and semaglutide carry identical gallbladder risk. | Not what the label data shows. In placebo-controlled pools, Mounjaro reported 0.6% vs 0% for acute gallbladder disease; Wegovy injection reported 1.6% vs 0.7% for cholelithiasis alone. Trial designs differ, so this is not head-to-head proof — but the numbers aren't identical either. |
| Lilly won't allow people without a gallbladder to take Mounjaro. | Misreading. Lilly's medical-information statement says they "cannot provide treatment recommendations" because no subgroup analysis was done. That's not a ban. Patients with prior cholecystectomy were not excluded from trials. |
| If you lose weight slowly, you won't get gallstones. | Oversimplified. Slower weight loss reduces risk (the Weinsier 1995 analysis identified a sharp increase above ~1.5 kg per week). But the Wegovy and Saxenda labels state directly that the gallbladder signal exceeded placebo even after adjusting for the degree of weight loss. The drug-related effect is separate from and additive to the rapid-weight-loss effect. |
Warning signs: which gallbladder symptoms on a GLP‑1 are urgent?
Answer capsule
Severe or persistent upper-right-abdominal pain — especially with fever, yellow skin or eyes (jaundice), clay-colored stools, dark urine, or repeated vomiting — needs urgent medical evaluation. Recurrent right-upper-quadrant discomfort after meals should trigger a prompt prescriber message and a question about whether to hold your next dose. A single mild, brief episode that fully resolves can be documented and mentioned at your next visit — but don't ignore it if it comes back.
This table is not a diagnosis or a medication-stop order. Severe symptoms need urgent care. Non-severe symptoms need prescriber guidance — your prescriber decides whether to hold or adjust your dose.
| 🔴 Urgent care or ER now — don't take another dose until a clinician tells you what to do | 🟡 Call your prescriber promptly; ask whether to hold the next dose | 🟢 Document and mention — watch for recurrence |
|---|---|---|
| Severe right-upper-quadrant pain lasting more than 2 hours | Brief right-upper pain after fatty meals that resolves but keeps coming back | Mild, single, short episode that fully resolves and doesn't return |
| Fever over 100.4°F with abdominal pain | New mild upper-right pain that recurs over a few days | Vague digestive discomfort that doesn't match the above patterns |
| Yellow skin or yellow eyes (jaundice) | Pain that improves with antacids but keeps returning | Routine nausea that's improving with each week |
| Clay-colored or pale stools | Nausea plus a new "twinge" under the right ribs | |
| Dark urine (the color of cola) | ||
| Persistent vomiting — can't keep fluids down | ||
| Pain that spreads to the back or right shoulder + fever | ||
| Pain so severe you can't find a comfortable position |
GLP‑1 nausea vs. gallbladder pain — how to tell them apart
- GLP‑1 nausea is usually all over the upper stomach, gets worse for a few hours after eating, and improves as you titrate. It's annoying. It's rarely sharp or localized.
- Gallbladder pain is usually right under the right ribs or in the upper-middle stomach, can radiate to the back or right shoulder, often shows up 30–60 minutes after a heavy or fatty meal, and can last for hours. It's not improving on its own each week.
If you're not sure: call your prescriber. That's literally what they're there for. It's not a stupid question. It's the right question.
How much does GLP‑1 treatment really raise your gallbladder risk?
Answer capsule
Class-level meta-analysis estimates the relative risk of gallstones at about 1.27–1.46× compared to placebo, with the weight-loss subgroup running about 2.29×. In absolute terms, that translates to roughly 2 extra cases per 1,000 patients. Risk is higher with higher doses, longer treatment duration, and faster weight loss.
He et al. 2022 in JAMA Internal Medicine (76 RCTs, 103,371 patients):
- Composite gallbladder or biliary disease: RR 1.37 (95% CI 1.23–1.52)
- Cholelithiasis: RR 1.27 (95% CI 1.10–1.47)
- Cholecystitis: RR 1.36 (95% CI 1.14–1.62)
- Biliary disease: RR 1.55 (95% CI 1.08–2.22)
- Weight-loss subgroup (high-dose GLP‑1 for obesity): RR 2.29 (95% CI 1.64–3.18)
A 2025 Gastroenterology systematic review (5-database pooled analysis) confirmed an RR of 1.46 (1.09–1.97) for cholelithiasis — about 2 more cases per 1,000 patients than placebo.
Where each claim comes from (and what it doesn't prove)
| Claim | Source | What it supports | What it doesn't prove |
|---|---|---|---|
| Rapid weight loss raises gallstone risk | NIDDK; Weinsier 1995 | Mechanism and a ~1.5 kg/week risk inflection point | Any specific individual's outcome on GLP-1 |
| Drug-related signal beyond weight loss | Wegovy and Saxenda labels: "greater than placebo even after accounting for degree of weight loss" | A medication-associated effect on top of rapid-weight-loss risk | That the drug caused any one person's gallstones |
| ~1.27× class-level relative risk for gallstones | He et al. 2022 JAMA Internal Medicine meta-analysis | Pooled class-level signal across 76 RCTs | A clean per-drug ranking |
| ~2 more cases per 1,000 patients | 2025 Gastroenterology systematic review | Absolute-risk framing for the typical mixed population | Personal risk if you have a history |
What this looks like in real life
Take 1,000 people who would have started a GLP‑1 for weight loss. In a placebo arm with a comparable lifestyle plan, maybe 7 of them get a gallstone diagnosis. In the active-drug arm, maybe 16 of them do. That's a ~2× relative increase. It's also a ~1 percentage-point absolute increase. Most people on the drug don't develop gallstones. Some do.
If you have an active gallstone history sitting in the background of those numbers — silent stones, prior attacks, prior cholecystitis — your personal baseline is higher than the average trial participant. That doesn't mean the GLP‑1 will cause an event. It means the math nudges in your direction, and it's a reason to take monitoring seriously.
Is it the drug or just the rapid weight loss?
Answer capsule
Both. Rapid weight loss above approximately 1.5 kg per week sharply raises gallstone risk on its own. The Wegovy and Saxenda labels also state directly that gallbladder events exceeded placebo even after accounting for the degree of weight loss, supporting a drug-related signal on top of the rapid-weight-loss effect.
The weight-loss mechanism. When you lose weight quickly, your liver secretes more cholesterol into bile. Bile becomes more saturated — the textbook setup for cholesterol gallstone formation. The classic Weinsier et al. analysis (1995) found gallstone risk increases roughly exponentially above 1.5 kg per week. NIDDK and decades of bariatric-surgery data reinforce the same threshold.
The drug mechanism. GLP‑1 receptor activation reduces cholecystokinin (CCK) signaling. CCK is the hormone that tells your gallbladder to squeeze and empty after a meal. Less CCK means slower gallbladder emptying. Slow emptying means bile sits longer, and bile that sits forms sludge, and sludge forms stones.
So: it's a stack. Rapid weight loss raises baseline risk. Slower gallbladder motility raises it again. Add a prior gallstone history underneath, and the math gets less abstract. The honest answer to "did the GLP‑1 cause my gallstones?" is: maybe; the weight loss may have been the driver; you may have had stones already that the weight loss made symptomatic; or all three contributed.
Which GLP‑1 has the lowest gallbladder signal in clinical trials?
Answer capsule
You can't cleanly rank GLP‑1s by gallbladder safety from label percentages alone. The cleaner framing is what's the safest plan — not which drug has the lowest trial number. Trial populations, doses, follow-up windows, and definitions of gallbladder events all differ.
That said — if you're weighing two real options with meaningful gallstone history, here's what the numbers do and don't tell us:
- Tirzepatide (Mounjaro / Zepbound) looks numerically lower in some label-reported trial pools, and in the 2025 Frontiers in Pharmacology FAERS pharmacovigilance analysis. FAERS analyses can generate post-market safety signals, but they cannot prove true incidence or rank personal risk.
- Foundayo (orforglipron) posted small absolute rates in its 2026 approval label — 1% vs 0.7% placebo.
- Saxenda (liraglutide 3.0 mg) and Wegovy tablets posted the highest absolute rates on this page (2.2% and 2.5% respectively).
The safest plan — regardless of drug — includes:
- Disclose your gallstone history in detail
- Start at the lowest dose; titrate slower than the standard schedule when reasonable
- Aim for weight loss closer to 0.5–1 kg per week, not 1.5+ kg per week
- Don't skip meals or stack a parallel very-low-fat diet
- Stay hydrated
- Know your red-flag symptoms and the triage box above
- For some patients with high prior risk, discuss UDCA (ursodiol) prophylaxis with your prescriber
Compare specific GLP‑1 options
Can you take a GLP‑1 after gallbladder removal?
Answer capsule
Yes — prior cholecystectomy is not listed as a contraindication for the GLP‑1 products covered here. Lilly explicitly states their tirzepatide products are not contraindicated in patients with prior gallbladder disease or removal, though no subgroup analysis was performed. You can no longer form classic gallbladder stones without a gallbladder, but bile-duct stones (choledocholithiasis) remain uncommonly possible, and post-cholecystectomy GI patterns can overlap with normal GLP‑1 side effects.
What changes physiologically after your gallbladder is removed: bile flows continuously from your liver into your intestine rather than being stored and released in pulses with meals. Most people adjust without issues. Some people develop "post-cholecystectomy syndrome" with bile-acid diarrhea, post-meal cramping, or fat intolerance.
Bowel changes can stack. GLP‑1s commonly cause diarrhea or loose stools during titration. So can post-cholecystectomy bile-acid diarrhea. If you already had post-surgery bowel issues, they may be louder during titration.
Fatty meals can hurt more. Without a gallbladder regulating bile delivery, large fatty meals can cause discomfort. GLP‑1s slow gastric emptying, which adds a second layer. The pragmatic solution: smaller meals, lower-fat portions, slower eating.
Post-cholecystectomy disclosure checklist
Before starting a GLP‑1 after gallbladder removal, your prescriber should know:
- Surgery date and reason (stones / cholecystitis / pancreatitis / other)
- Whether you had any complications (pancreatitis, bile leak, retained stones)
- Any ongoing bile-acid diarrhea or post-meal symptoms
- Any history of bile-duct stones or biliary work-up since surgery
- Current digestion status — regular meals, current weight, current GI patterns
Can you take a GLP‑1 if you've had gallstone pancreatitis?
Answer capsule
This is the highest-attention gallbladder history on this page. Gallstone pancreatitis is not listed as a contraindication, but it warrants individualized review by your prescriber, and ideally a gastroenterologist, before starting. Acute pancreatitis is a separate Warnings and Precautions issue across these products — every relevant label tells prescribers to watch for pancreatitis symptoms and discontinue the medication if pancreatitis is suspected.
If your gallstones caused pancreatitis at any point, you have two concerns running in parallel, and you should not start a GLP‑1 by clicking through a telehealth quiz without your full history in front of a clinician who reads it carefully.
The two concerns:
- Pancreatitis risk on GLP‑1s. Every product reviewed here carries a Warnings and Precautions section for acute pancreatitis. Rates in trials are low but real. Your prior pancreatitis episode raises your personal baseline.
- Recurrent gallstone disease. If your gallbladder is still in place and your stones caused pancreatitis once, they can do it again. Rapid weight loss can move stones. Reduced gallbladder emptying from GLP‑1 effects can promote new stones.
What to do:
- Disclose this history in full. Date, severity, hospitalization details if you have them.
- Make sure your prescriber sees imaging and labs, not just your verbal history.
- Discuss whether you need GI specialist input before starting.
- If your gallbladder is still in place after a pancreatitis episode, ask your prescriber about the risk of recurrence specifically.
- Ask what symptoms should trigger an urgent call back to them.
This is not automatically a "you can't take it" scenario. It is a "this needs a proper conversation, not a checkbox" scenario.
How to lower your gallstone risk on a GLP‑1 (practical prevention)
Answer capsule
Practical, prescriber-directed risk-reduction steps include slower titration when clinically reasonable, avoiding crash dieting, keeping weight loss from becoming extremely fast, eating regular balanced meals, staying hydrated, and — for selected high-risk patients — asking about ursodeoxycholic acid (UDCA, ursodiol). UDCA has evidence for rapid weight loss through very-low-calorie diets and after bariatric surgery; its use during GLP‑1 weight loss is off-label and not standard for everyone.
Prevention lever: GLP‑1-specific or extrapolated?
| Action | Evidence source | GLP‑1-specific? | What to ask your prescriber |
|---|---|---|---|
| Slower titration | Clinical practice; product labels permit individualized titration | No formal GLP-1 gallstone-prevention protocol | "Can we hold this dose longer if my weight is falling fast?" |
| Weight loss closer to 0.5–1 kg/week | NIDDK; Weinsier 1995 | No — general weight-loss guidance | "What rate of loss should we target for me specifically?" |
| Regular balanced meals, some dietary fat | NIDDK | No — general gallstone-prevention guidance | "Should I avoid very-low-fat patterns while titrating?" |
| Hydration | General clinical guidance | No — general | "What signs of dehydration should I watch for?" |
| UDCA (ursodiol) prophylaxis | NIDDK supports during very-low-calorie diets/bariatric surgery; 2023 Cureus meta-analysis (12 RCTs) | Extrapolated — not FDA-approved or standard for GLP-1 weight loss | "Given my history, would UDCA make sense for me?" |
Slow your titration when reasonable
Many injectable GLP‑1 schedules increase the dose after about 4 weeks, but schedules vary by product. There's nothing magical about 4 weeks. If you're tolerating well and your weight is falling faster than 1.5 kg per week, holding a dose longer is reasonable for many patients. The goal is steady, sustained loss — not the fastest possible.
Keep weight loss under ~1.5 kg per week
The Weinsier et al. 1995 analysis is still the cleanest evidence on the threshold. Gallstone formation risk rises roughly exponentially above 1.5 kg per week (about 3.3 pounds). If your scale shows 4+ pounds of loss per week consistently, that's faster than the gallstone literature recommends. Talk to your prescriber about slowing the pace.
Don't skip meals; keep some fat in your diet
Common sense says "if I'm trying to lose weight on a GLP‑1, I should eat as little as possible." Common sense is wrong here. Skipping meals lets your gallbladder sit full without contracting. Bile concentrates. Sludge forms. Stones can follow. A small, regular amount of dietary fat — avocado, olive oil, nuts, salmon — actually triggers normal gallbladder emptying. Very-low-fat patterns can be counterproductive for gallstone prevention. NIDDK explicitly warns that prolonged fasting and very-low-calorie diets increase gallstone risk during weight loss.
Ask about ursodeoxycholic acid (UDCA / ursodiol) — prescriber decision
UDCA is a bile acid that reduces cholesterol saturation in bile and lowers cholesterol gallstone formation during rapid weight loss. NIDDK specifically notes that ursodiol can help prevent gallstones in people losing weight rapidly through very-low-calorie diets or weight-loss surgery. A 2023 Cureus meta-analysis of 12 randomized trials and 2,767 patients showed UDCA prophylaxis significantly reduces symptomatic cholelithiasis and cholecystectomy rates after bariatric surgery. Important caveat: UDCA is not FDA-approved for prophylaxis during GLP‑1 weight loss specifically. Some clinicians use it off-label for high-risk patients — it's not standard of care. Individual decision only.
What to tell your prescriber: the exact intake script
Answer capsule
Bring a precise, specific gallbladder history instead of saying "I had gallstones." Your prescriber needs to know whether the stones were silent or symptomatic, whether you had cholecystitis, whether you had pancreatitis, whether your gallbladder is still in place, and whether you currently have symptoms.
The 60-second disclosure script — copy and fill in
Gallbladder history:
- Gallstones first found: [year], [reason — symptoms / incidental finding]
- Symptoms history: [none / biliary colic episodes — count, last date / cholecystitis / gallstone pancreatitis]
- Imaging history: [most recent ultrasound or CT and findings, year]
- Surgery: [no / yes, cholecystectomy in (year), reason]
- Current symptoms: [none / occasional / list specific symptoms]
- Currently on a GLP-1: [no / yes, drug, dose, weeks on therapy]
- Recent weight-loss rate: [pounds per week, if known]
Questions to ask before you start
- Does my specific gallbladder history change whether I should start this drug, or just how we monitor?
- Do I need an ultrasound or labs (liver enzymes, lipase) before starting?
- Should I titrate slower than the standard schedule given my history?
- What rate of weight loss should we target for me specifically?
- What symptoms should make me call you before my next dose?
- What symptoms mean go to the ER without calling first?
- For my history, would you consider UDCA prophylaxis?
- If I had gallstone pancreatitis, does that change the answer for me?
Questions to ask if you're already on a GLP‑1 and something feels off
- I've been having [describe symptom]. Is this gallbladder-related or normal GI side effects?
- Should I hold my next dose until you evaluate me?
- Do I need imaging now, or can it wait until my next appointment?
- If this turns out to be gallstones, what happens next — do we stop the medication, change drugs, or treat the gallstones?
What we verified — and what we can't promise
What we verified (all May 15, 2026):
- ✅ Wegovy, Wegovy HD, Wegovy oral, Ozempic, Rybelsus, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, and Foundayo current FDA Prescribing Information sections on Contraindications, Warnings/Precautions, and Adverse Reactions related to gallbladder disease
- ✅ He et al. 2022 JAMA Internal Medicine meta-analysis (76 RCTs, n=103,371)
- ✅ 2025 Gastroenterology systematic review on GLP-1 RA gastrointestinal adverse events
- ✅ 2025 Frontiers in Pharmacology FAERS pharmacovigilance analysis
- ✅ Lilly's official medical-information statements on tirzepatide and gallbladder disease/removal
- ✅ NIDDK guidance on dieting, weight loss, and gallstones
- ✅ Weinsier et al. 1995 analysis of weight-loss rate and gallstone risk
- ✅ 2023 Al-huniti et al. Cureus meta-analysis of UDCA prophylaxis after bariatric surgery
What remains uncertain:
- Your personal risk of a gallstone event on any specific GLP‑1
- Whether you should start, continue, switch, or stop a medication
- A clean head-to-head ranking of GLP‑1 drugs for gallstone-history patients (the trials weren't designed that way)
- Drug labels updated after our last-verified date — labels change, and we update this page quarterly
How to use this page safely. Use this page to: understand the scenarios, recognize red flags, prepare specific questions for your prescriber, complete a telehealth intake honestly, and tell the difference between routine GLP‑1 nausea and a gallbladder warning sign. Don't use this page to: self-prescribe, self-stop, decide a drug is "safe enough" for you without prescriber input, or ignore symptoms.
Frequently asked questions
Can GLP-1 medications actually cause gallstones?
GLP-1 receptor agonists are associated with an increased risk of gallstones in randomized clinical trials. The class-level relative risk in the He et al. 2022 JAMA Internal Medicine meta-analysis was 1.27 for cholelithiasis. Both the weight loss and the medication contribute — the labels say the signal exceeded placebo even after adjusting for weight loss.
Are gallstones a contraindication for Ozempic?
No. Ozempic's listed contraindications are personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, and prior serious hypersensitivity to semaglutide. Gallstone history is not on that list. Ozempic's label does include cholelithiasis trial data (1.5% at 0.5 mg vs 0% placebo) and a Warnings and Precautions section on acute gallbladder disease.
Can I take Wegovy if I have gallstones?
Possibly. A history of gallstones is not a Wegovy contraindication. The decision depends on whether your stones are silent, symptomatic, complicated by cholecystitis or pancreatitis, or accompanied by current pain. Wegovy's label reports cholelithiasis in 1.6% of adult weight-management patients vs 0.7% on placebo. If your stones are silent and your gallbladder is intact, you may still be a candidate — disclose your history to your prescriber and get a monitoring plan.
Can I take Mounjaro if I have gallstones?
Gallstone history is not a Mounjaro contraindication. Mounjaro's placebo-controlled adult trial pool reported acute gallbladder disease in 0.6% of patients vs 0% placebo. Lilly's medical-information statement says they cannot make individual treatment recommendations and no subgroup analysis was done for patients with prior gallbladder disease — but patients with prior gallbladder disease were not excluded from trials.
Can I take Zepbound after gallbladder removal?
Prior cholecystectomy is not a Zepbound contraindication. Lilly notes patients with prior gallbladder disease or removal were not excluded from SURMOUNT trials, though no subgroup analysis was performed. You'll still want to disclose the surgery date, reason, and any ongoing post-surgery GI symptoms to your prescriber.
Is Foundayo (orforglipron) safer for the gallbladder?
In its 2026 approval trials, Foundayo reported cholelithiasis in 1% of patients vs 0.7% placebo and cholecystitis in 0.4% vs 0.3% placebo. Those are small absolute numbers. Whether that translates to a meaningful clinical advantage for a specific patient with gallstone history requires more real-world data than exists at this writing.
Is the high-dose Wegovy HD (7.2 mg) higher risk for gallstones?
The class evidence (He et al. 2022 meta-analysis) shows higher doses and longer treatment correlate with higher gallbladder risk. Wegovy HD 7.2 mg was approved by FDA in March 2026. Its label includes 7.2 mg safety data, but the gallbladder warning section does not provide a clean dose-specific cholelithiasis rate for the 7.2 mg group apart from the standard adult injection figures.
Should I get an ultrasound before starting a GLP-1?
Not routinely. Major guidance does not recommend baseline ultrasound for asymptomatic patients with no prior gallstone history. For patients with prior symptomatic stones and an intact gallbladder, a baseline ultrasound is reasonable and worth asking your prescriber about. If symptoms appear during therapy, the threshold for imaging should be low.
Should I stop my GLP-1 if I get right-upper-abdominal pain?
Don't self-manage severe or persistent upper-abdominal pain. Contact your prescriber promptly, and seek urgent care if pain is severe or accompanied by fever, jaundice, repeated vomiting, clay-colored stools, or dark urine. For brief, mild symptoms that resolve, message your prescriber and ask whether to hold the next dose; do not dose-escalate while symptoms are unexplained.
Is gallbladder pain the same as GLP-1 nausea?
No. GLP-1 nausea is usually diffuse upper-stomach, meal-related, and improves with each week of titration. Gallbladder pain is usually localized to the right upper quadrant or upper-middle abdomen, can radiate to the back or right shoulder, often lasts for hours, and may follow heavy or fatty meals.
Can ursodiol (UDCA) prevent gallstones while I'm on a GLP-1?
UDCA has strong evidence for preventing gallstones during rapid weight loss after bariatric surgery (2023 Cureus meta-analysis) and NIDDK notes it can help during very-low-calorie diets and weight-loss surgery. It is not FDA-approved for prophylaxis specifically during GLP-1 weight loss, and large randomized trials in that population don't yet exist. Some clinicians use it off-label for high-risk patients. Ask your prescriber if it's appropriate for your case.
What if I had gallstone pancreatitis — is GLP-1 therapy out?
Not automatically. Gallstone pancreatitis is not a listed contraindication, but it is a higher-attention history. Many prescribers want GI specialist input, want full records of the pancreatitis episode, and want a slower start and closer monitoring. It's a "real conversation" history, not a "fill in a quiz" history.
What should I write on a telehealth intake form?
Be specific. Use the disclosure script in the prescriber section. Include: when stones were found, whether they were symptomatic, any history of cholecystitis or pancreatitis, whether your gallbladder is still in place, and any current symptoms. Don't omit the history to speed approval — if a provider declines or asks for more information, that's a safety screen, not a personal failure.
Does losing weight slowly mean I won't get gallstones on a GLP-1?
It lowers your risk but doesn't eliminate it. The Wegovy and Saxenda labels are clear that the gallbladder signal in trials exceeded placebo even after adjusting for the rate of weight loss. So slower weight loss helps. It just doesn't make the drug-related signal disappear.
Related safety and comparison guides
Sources and references — all verified May 15, 2026
FDA Prescribing Information (accessdata.fda.gov):
- Wegovy (semaglutide) injection — current revision: accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
- Ozempic (semaglutide) injection: accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- Zepbound (tirzepatide): accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
- Mounjaro (tirzepatide): accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
- Saxenda (liraglutide): accessdata.fda.gov/drugsatfda_docs/label/2026/206321s025lbl.pdf
- Trulicity (dulaglutide): accessdata.fda.gov/drugsatfda_docs/label/2026/125469s065lbl.pdf
- Foundayo (orforglipron) — initial U.S. approval 2026: accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
Peer-reviewed publications:
- He L et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Internal Medicine. 2022;182(5):513–519.
- Gastroenterology 2025 systematic review of GLP-1 RA gastrointestinal adverse events.
- Frontiers in Pharmacology 2025 FAERS pharmacovigilance analysis of GLP-1 RA biliary and gastrointestinal events.
- Weinsier RL et al. Medically safe rate of weight loss for the treatment of obesity. Am J Med. 1995.
- Al-huniti M et al. Ursodeoxycholic Acid Prophylaxis After Bariatric Surgery. Cureus. 2023.
Manufacturer and government guidance:
- Eli Lilly medical information — tirzepatide use in patients with history of gallbladder disease or prior gallbladder removal.
- NIDDK: Dieting and Gallstones; Gallstones — Symptoms and Causes.
- Merck Manual Professional Version: Cholelithiasis.
Disclosure
By the Weight Loss Provider Guide Editorial Team · Last verified: May 15, 2026 · Next scheduled update: August 15, 2026, or sooner if any drug's label is revised.
This page is informational and educational. It is not medical advice, a clearance to start any medication, or a substitute for a relationship with a licensed prescriber. If you're having severe abdominal pain, fever, jaundice, persistent vomiting, dark urine, or clay-colored stools, seek urgent medical care.
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Zepbound®, Mounjaro®, Foundayo™, and Trulicity® are trademarks of Eli Lilly and Company. Saxenda® is a registered trademark of Novo Nordisk A/S. Weight Loss Provider Guide is not affiliated with or endorsed by Eli Lilly and Company or Novo Nordisk A/S.